NeoStem, Inc. - "Are All Cardiovascular Cell Therapies Created Equal?"

Publishing & Media

Share Tweet

NeoStem, Inc. - "Are All Cardiovascular Cell Therapies Created Equal?"

Pittsburgh, PA / May 5, 2014 / NeoStem, Inc. (NASDAQ: NBS) today published a new blog post on The Chairman's Blog, written by the Company's Chief Medical Officer Dr. Douglas W. Losordo. is an exclusive online media publication that enables key executive officers a unique platform to share insights about their company and industry trends.

Dr. Losordo writes about what sets NeoStem's cardiovascular cell therapy, AMR-001, apart from other bone marrow (BM) derived cell therapies. He highlights AMR-001's three key differentiators which he believes make it a "unique BM derived cell therapy." Read the full blog post from Dr. Losordo on (

About NeoStem, Inc.

NeoStem is a leader in the emerging cellular therapy industry, pursuing the preservation and enhancement of human health globally through the development of cell based therapeutics that prevent, treat or cure disease by repairing and replacing damaged or aged tissue, cells and organs and restoring their normal function. The business includes the development of novel proprietary cell therapy products as well as a revenue-generating contract development and manufacturing service business. This combination has created an organization with unique capabilities for cost effective in-house product development and immediate revenue and cash flow generation.

About is an exclusive, online media publication where publicly and privately held firms alike share insights about their companies and industries. enables upper tier management to discuss issues that are of importance to their stakeholders, shareholders, and interested parties in an informal environment.


SOURCE: NeoStem, Inc. and